Ambroxol therapy in simple chronic bronchitis: effects on subjective symptoms and ventilatory function.

Area of Science:

• Pharmacology
• Respiratory Medicine

Background:

• Chronic bronchitis is a common respiratory condition characterized by persistent cough and mucus production.
• Ambroxol, a mucolytic agent and metabolite of bromhexine, is used to treat respiratory diseases.

Purpose of the Study:

• To evaluate the efficacy and safety of ambroxol in patients with simple chronic bronchitis.
• To compare the effects of two different daily dosages of ambroxol (60 mg and 120 mg) against a placebo.

Main Methods:

• A double-blind, parallel-group, placebo-controlled trial was conducted.
• Ninety-seven subjects with simple chronic bronchitis were enrolled, with 92 completing the study.
• Data were collected through subjective interviews, patient diary cards, and lung function tests.

Main Results:

• The 120 mg ambroxol group showed significantly greater improvement in respiratory symptoms, especially expectoration, compared to the placebo group.
• Patients in the 120 mg ambroxol group tended to prefer the treatment over placebo.
• No significant changes were observed in lung function tests during the treatment period.

Conclusions:

• Ambroxol demonstrates a symptomatic benefit in patients with simple chronic bronchitis, primarily by improving expectoration.
• Further research in patients with more severe chronic bronchitis is recommended to fully ascertain ambroxol's therapeutic potential.